The inhibition of EphA4 is most likely to modify the early stage of ALS and maintain motor neuron alive, resulting in improvements in the functional performance during ALS disease progression; however, it is unlikely to alter longitudinal motor neuron death at the end of disease. Here, EPHA4 is linked to amyotrophic lateral sclerosis.